Which Protocol-Tracking Metrics Best Capture Adherence and Response for Peptide Stack Self-Experimenters in 2026?

Five metric categories best capture adherence and response for peptide stack self-experimenters in 2026: per-compound proportion of days covered (PDC), dose-timing variance score, injection-site rotation index, compound-specific biomarker response windows, and structured subjective response scoring. No single metric is sufficient — adherence metrics confirm exposure fidelity while response metrics confirm whether the mechanistic window was reached.

The distinction between adherence metrics and response metrics is operationally critical for multi-compound stacks. Adherence metrics measure whether the protocol was executed as designed. Response metrics measure whether that execution produced a detectable signal in the target pathway. A self-experimenter can achieve 95% adherence and still generate no interpretable response data if response metrics were never defined before the protocol started.

This post maps each metric category to its measurement method, its failure mode, and the stack-design implication it generates. The framework draws from N-of-1 trial methodology, digital-health adherence literature, and compound-specific pharmacokinetic data. No peptide-specific RCT validates the full framework — the inference chain is built from adjacent evidence domains applied to the self-experimentation context.

Why Is Per-Compound PDC a More Reliable Adherence Metric Than an Aggregate Stack Score in 2026?

Proportion of days covered (PDC) calculated per compound — not per stack — is the most structurally sound adherence metric for multi-peptide protocols. The Pharmacy Quality Alliance endorses PDC over MPR because PDC cannot exceed 100% and resists inflation from dose stockpiling. Applied per compound, PDC surfaces the specific agent failing adherence while the aggregate score remains visually acceptable.

The aggregate-score masking problem is the primary failure mode of stack-level adherence tracking. A three-compound stack where one compound is logged at 100%, a second at 90%, and a third at 40% produces an aggregate score of approximately 77% — visually acceptable in a dashboard. The third compound's pathway is effectively absent from the protocol. PDC calculated per compound makes this gap explicit.

For peptide stacks, the PDC calculation window must match the protocol's mechanistic timeline. PDC is typically calculated over 90-day or 180-day windows in clinical adherence research. A six-week peptide protocol compressed into that window will show artificially high PDC if the denominator is set to 90 days. Protocol designers should set the PDC window to the planned protocol duration, not to a generic clinical reference period.

A second structural advantage of per-compound PDC is compound-specific dropout detection. In a CJC-1295 + Ipamorelin + BPC-157 stack, the GH-axis compounds and the tissue-repair compound operate on different onset timelines. A PDC drop on BPC-157 in week three does not affect the GH-axis signal — but it eliminates the repair-pathway data entirely. Per-compound PDC makes this asymmetric dropout visible in real time.

What Does Dose-Timing Variance Score Measure, and Why Does It Matter for Peptide Stacks?

Dose-timing variance score measures the standard deviation of actual injection times relative to the scheduled window, expressed in minutes. For GH-axis secretagogues dosed around sleep onset, high timing variance degrades the pharmacological signal even when PDC remains at 100%. A self-experimenter can be fully adherent by dose count while being pharmacologically inconsistent by timing.

Chronopharmacology research establishes that circadian variation in drug ADME is clinically significant across multiple compound classes. For GH-releasing peptides, the GH pulse architecture is tightly coupled to slow-wave sleep onset. A 2025 Endocrine Reviews analysis of hormone administration chronobiology confirmed that circadian variability in pharmacokinetics is measurable within a 24-hour injection window for GH-axis agents.

The practical measurement unit is straightforward: log the scheduled injection time and the actual injection time for every dose event. Calculate the standard deviation across all logged events for each compound. A variance score below ±30 minutes is operationally consistent for most peptide protocols. A variance score above ±90 minutes on a GH-axis compound signals that the timing-sensitive pharmacological window is being missed on a meaningful fraction of doses.

Dose-timing variance is distinct from missed-dose tracking. A self-experimenter who consistently injects two hours later than scheduled will show 100% PDC and a high timing variance score simultaneously. PDC alone cannot detect this pattern. The two metrics are complementary, not redundant.

How Should Self-Experimenters Track Injection-Site Rotation as a Protocol Metric?

Injection-site rotation index tracks distinct anatomical sites used per rolling seven-day window as a ratio of unique sites to total injections. Subcutaneous lipodystrophy — abnormal fat accumulation or loss at repeated injection sites — is documented in insulin literature at incidence rates of 25–50% in non-rotating patients. Lipodystrophy alters subcutaneous tissue architecture and degrades peptide absorption consistency.

The mechanism is well-characterised in insulin delivery research. A 2016 PMC analysis (Gentile et al.) documented that lipodystrophy from repeated subcutaneous injections produces fibrotic tissue that slows absorption and increases pharmacokinetic variability. For peptide self-experimenters running daily injection protocols, the same mechanism applies.

A self-experimenter injecting BPC-157 daily into the same abdominal quadrant for six weeks is systematically degrading the absorption consistency of every subsequent dose. The fibrotic tissue accumulation is cumulative and not immediately perceptible — making it a silent confound in response data unless the rotation index is tracked explicitly.

The rotation index is calculated as: (unique sites used ÷ total injections in the window) × 100. A score of 25 means one unique site per four injections — appropriate for a four-site rotation on a daily protocol. A score below 20 on a daily protocol signals site reuse at a frequency associated with lipodystrophy risk. Protocol apps that include injection-site mapping generate this index automatically from logged site data.

Which Biomarker Response Windows Are Compound-Specific, and How Should They Be Scheduled?

Biomarker response windows are compound-specific and must be scheduled against each peptide's known mechanistic onset timeline. For GH-axis secretagogues, serum IGF-1 is the primary response biomarker, with detectable elevation typically appearing within one to four weeks per CJC-1295 pharmacokinetic data. For inflammatory-pathway peptides, high-sensitivity CRP panels are the relevant response markers, with timelines of two to six weeks.

The Sackmann-Sala et al. (2009, PMC2787983) CJC-1295 study in healthy adult males demonstrated measurable serum IGF-1 elevation and associated protein profile changes within one week of a single long-acting GHRH analog administration. For self-experimenters running a pulsatile GHRH/GHRP stack, this establishes a minimum biomarker check-in window of week two. That timing is early enough to confirm GH-axis response, yet late enough for the signal to clear baseline noise.

Scheduling biomarker checks against the wrong timeline is the primary failure mode of response tracking. A self-experimenter who checks IGF-1 at week one of a Sermorelin protocol may see no change — not because the compound is inactive, but because cumulative pulsatile GH stimulation has not yet produced a sustained IGF-1 elevation. Compound-specific response windows should be logged as protocol milestones before the protocol starts, not decided reactively.

For stacks targeting tissue repair endpoints — TB-500, GHK-Cu, collagen-synthesis peptides — functional performance metrics such as grip strength, range of motion, and pain scale scores are more accessible response proxies than serum biomarkers. These should be logged at baseline and at the compound's minimum mechanistic onset window, which preclinical data places at four to six weeks for TB-500's systemic actin-sequestration effects.

How Should Structured Subjective Response Scoring Be Designed to Generate Interpretable N-of-1 Data?

Structured subjective response scoring uses fixed-scale daily ratings on pre-specified dimensions — sleep quality, energy, recovery speed, pain level — logged consistently across the full protocol window. The N-of-1 trial framework identifies this as a valid primary outcome measure when the scale is defined before the protocol starts and analyzed against a pre-protocol baseline of equal length.

The critical design requirement is pre-specification. A self-experimenter who starts logging "energy level" in week three — after noticing a subjective change — has introduced recall bias and selection bias simultaneously. The baseline period must be logged before the first compound is administered. A minimum of seven days of pre-protocol baseline scoring on each dimension provides the comparison anchor that makes within-subject change interpretable.

Rating scale granularity matters. A binary yes/no daily log generates insufficient variance to detect gradual changes. A 1–10 numeric rating scale applied to three to five pre-specified dimensions — sleep quality, morning energy, recovery speed, local pain, and overall wellbeing — generates enough data points across a six-week protocol to calculate a within-subject effect size.

Subjective response scores should be logged blind to the adherence data during the active protocol period. Reviewing PDC scores before logging a subjective rating introduces expectation bias. Separating the two data streams until the protocol ends preserves the independence of the response signal.

Stack Blueprint: Five-Metric Tracking Framework for a GH-Axis and Repair Stack

The following blueprint maps a representative GH-axis plus tissue-repair stack against all five metric categories. Each metric is assigned a measurement method, check-in frequency, concern threshold, and the failure mode it detects. This is a structural reference for protocol designers — not a dosing recommendation or clinical protocol.

The five metrics operate as a layered diagnostic system. PDC and timing variance confirm that the pharmacological input was delivered correctly. The rotation index confirms that absorption consistency was maintained. Biomarker windows confirm that the target pathway responded.

Subjective scoring confirms whether the pathway response translated into a detectable within-subject experience. A protocol that passes all five checks generates interpretable N-of-1 data. A protocol that fails any one check has a structural gap that limits the interpretability of the others. The layered structure means that a high subjective response score on a protocol with poor rotation index data is not interpretable — the absorption variance is a confound that cannot be retrospectively controlled.

What Metric Gaps Remain Unresolved in 2026 for Multi-Compound Peptide Stacks?

Three metric gaps remain unresolved for multi-compound peptide stacks in 2026: no validated compound-interaction adherence metric detects when one compound alters another's pharmacokinetics; no standardized biomarker panel covers all mechanistic axes simultaneously; and subjective response scoring has no validated peptide-specific scale. These gaps limit N-of-1 data interpretability even when all five core metrics are tracked.

The compound-interaction adherence gap is the most structurally significant. Standard PDC and timing variance metrics assume that each compound's pharmacokinetics are independent. For stacks where one compound modulates a shared pathway — for example, a GLP-1 agonist co-administered with a GH secretagogue, where GLP-1R signaling has documented effects on GH pulsatility — the adherence metrics confirm exposure to both compounds but cannot detect whether the interaction is altering the effective pharmacological dose of either.

The biomarker panel gap reflects the absence of a validated multi-axis panel for peptide stack response. IGF-1 covers the GH axis and hsCRP covers inflammatory pathways. Neither covers the AMPK-mitochondrial axis relevant to MOTS-c, nor the actin-sequestration pathway relevant to TB-500. Self-experimenters tracking multi-axis stacks must assemble compound-specific biomarker panels from independent sources.

No standardized reference for multi-axis peptide biomarker panel assembly exists as of 2026. This means the biomarker response window metric — the most objective of the five — is also the least standardized. Protocol designers must document their panel-selection rationale explicitly, or the response data cannot be compared across protocols or individuals.

For cross-reference on interaction data that precedes metric design, see the CJC-1295 and Ipamorelin GH-axis mechanism monograph and the GH secretagogue IGF-1 body composition metrics analysis. What Human Dose-Response Data Exist for BPC-157 in Inflammatory Bowel Disease and Soft-Tissue Injury in 2026? How Does the Brain-Restricted Peptide BRP Suppress Appetite Without Causing Nausea in 2026 — and How Does It Compare to GLP-1 Drugs? How Does the Computationally Discovered BRP Peptide Compare to GLP-1 Agonists for Weight Loss Without Gastric Emptying Side Effects in 2026?